UAB invests over 22% of annual revenues in R&D. Our integrated discovery-to-development platform spans early target identification through to global regulatory submissions — with a single goal: delivering transformative medicines to patients faster.
Concentrated expertise in six disease areas where the unmet medical need is greatest and the science is most compelling.
Targeted therapies and immuno-oncology approaches for solid tumours and haematological malignancies, with a focus on resistance mechanisms and precision medicine.
Disease-modifying therapies for neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Novel lipid-lowering agents, anti-thrombotic therapies, and heart failure treatments addressing residual cardiovascular risk in high-risk patients.
Selective immunomodulatory approaches for autoimmune and inflammatory conditions including atopic dermatitis, psoriatic arthritis, and IBD.
Enzyme replacement therapies and gene therapy approaches for ultra-rare lysosomal storage disorders with significant unmet medical need.
Antifungal and antiviral agents targeting resistant pathogens of significant public health concern, with a focus on MENA-prevalent infections.
End-to-end internal capabilities from molecule to medicine.
AI-powered genomic and proteomic analysis to identify disease-relevant targets with strong genetic validation.
Multi-disciplinary teams designing and optimising small molecule drug candidates with superior selectivity and drug-like properties.
Cryo-EM and X-ray crystallography facilities enabling structure-based drug design for challenging target classes.
Biomarker development and patient stratification strategies to maximise proof-of-concept success rates in early clinical trials.
Phase I–III clinical trial design and execution across 23 countries with specialist CRO partnerships and in-house biometrics.
Integrated regulatory strategy from early development through to global submissions and post-marketing lifecycle management.
UAB actively pursues academic partnerships, CRO collaborations, and co-development agreements. Contact our BD team to explore opportunities.